Colorectal Cancer Clinical Trials

Colorectal cancer clinical trials are valuable tools that allow patients to benefit from new treatments as soon as they become available. At the same time, these important research studies help scientists and physicians improve the standard of care. During a trial, if a new treatment is found to be more effective than the currently available options, that treatment may become the new standard. In fact, all of today’s standard treatments were chosen based on the results of past clinical trials.

Patients who participate in colorectal cancer clinical trials at Moffitt Cancer Center can feel confident that they will:

  • Receive the best possible treatment to meet their individual needs in the form of either newly discovered therapies or the current standard of care
  • Be evaluated and monitored by a multispecialty team of cancer experts who will adhere to a carefully designed testing protocol and make highly individualized, evidence-based recommendations
  • Benefit other colorectal cancer patients by helping to improve the standard of care

Through our ongoing research efforts and robust portfolio of clinical trials, Moffitt is achieving better cancer outcomes and providing our patients with higher-quality lives. We are also continually moving forward by identifying causes, developing prevention strategies and discovering new and better treatments for colorectal cancer. As a result of this commitment, Moffitt has earned the distinction of being the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, a prestigious designation that is nationally recognized by medical professionals and patients alike. Thousands of patients come to Moffitt for innovative treatments and compassionate care.

If you’d like to learn more about the current colorectal cancer clinical trials at Moffitt, you do not need a referral. Call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.


calledFromCancerPage=True - substr=colorectal

Open Clinical Trials:

Showing of 50


Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) or Photon (IMRT) with Simultaneously Integrated Boost to the High Margin for Retroperitoneal Sarcomas

Disease Site: Anal, Colon, Kidney, Other genitourinary, Pancreas, Rectum, Sarcoma

View Trial Details


A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)

Disease Site: Any Site, Breast, Colorectal, Endometrial/Uterine, Extrapulmonary small cell lung cancer, Gallbladder, Gastric / Stomach, Gastrinoma, Gastrointestinal, Liver, Lung, Non small cell lung cancer, Other genitourinary, Other GI, Pancreas, Prostate, Reproductive System, Urinary Bladder, Uterus

View Trial Details


MRI Guided Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma to Enhance Complete Response

Disease Site: Rectum

View Trial Details


A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Disease Site: Any Site, Brain and Nervous System, Lung, Pancreas, Rectum, Brain metastasis, Leptomeningeal (LMD)

View Trial Details


A Phase 1/2 Study of Regn7075 (Egfrxcd28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors

Disease Site: Anus, Breast, Cervix, Colon, Esophagus, Kidney, Lip, Oral Cavity and Pharynx, Lung, Other Digestive Organ, Other Female Genital, Other Male Genital, Other Skin, Other Urinary, Pancreas, Prostate, Stomach

View Trial Details


A First-in-Human, Two-Part, Open-Label, Clinical Study to Assess the Safety, Tolerability and Activity of Intravenous Doses of ICT01 as Monotherapy and in Combination with an Immune Checkpoint Inhibitor, in Patients with Advanced-Stage, Relapsed/Refractory Cancer (EVICTION Study)

Disease Site: Any Site, Breast, Colon, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Ovary, Prostate, Stomach, Urinary Bladder

View Trial Details


A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination with Trastuzumab and Oxaliplatin-Based Chemotherapy for HER2+ Gastrointestinal Cancers

Disease Site: Colon, Esophagus, Liver, Rectum, Stomach

View Trial Details


A Phase 2 Open Label Study to Evaluate the Safety and Effectiveness of 212Pb-DOTAMTATE in PRRT Naïve Subjects with Somatostatin Receptor Expressing Neuroendocrine Tumors

Disease Site: Any Site, Liver, Lung, Other Digestive Organ, Other Endocrine System, Pancreas, Rectum, Small Intestine, Stomach

View Trial Details


Screen to Save: NCI Colorectal Cancer Outreach & Screening Initiative

Disease Site: Colon, Rectum

View Trial Details


A Pre-Pilot of a Survivor-Personalized Colorectal Cancer Screening Education Intervention for Adult First-Degree Relatives

Disease Site: Colon, Rectum

View Trial Details


Transdisciplinary Research in Colorectal Cancer: The ColoCare Study

Disease Site: Colorectal, Colon, Rectum

View Trial Details